Rapid Dose Therapeutics Corp. reported earnings results for the third quarter and nine months ended November 30, 2022. For the third quarter, the company reported sales was CAD 0.305629 million compared to CAD 0.457724 million a year ago. Net loss was CAD 0.583504 million compared to CAD 0.790751 million a year ago. Basic loss per share from continuing operations was CAD 0.005 compared to CAD 0.008 a year ago.
For the nine months, sales was CAD 0.500949 million compared to CAD 1.61 million a year ago. Net loss was CAD 2.51 million compared to CAD 1.56 million a year ago. Basic loss per share from continuing operations was CAD 0.025 compared to CAD 0.015 a year ago.